Print

The IGBA

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in late 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA). 

IGBA is committed to promoting generic and biosimilar medicines by exchanging information worldwide through constant dialogue with the ICH, WHO, WTO, WIPO and other international organization.

IGBA consists of the following associations:

  • Association for Accessible Medicines (AAM-USA)
  • Canadian Generic Pharmaceutical Association (CGPA-Canada)
  • Generic & Biosimilar Medicines Southern Africa (GBM-Southern Africa)
  • Japan Generic Medicines Association (JGA-Japan)
  • Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordan)
  • Indian Pharmaceutical Alliance (IPA-India)
  • Medicines for Europe (Europe)
  • Taiwan Generic Pharmaceutical Association (TGPA-Taiwan)
  • In addition, the generic medicines associations of Australia, Mexico, Malaysia, Saudi Arabia, and Brazil are Associate Members

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site